AXIM Files Patent Application for Controlled-Release Chewing Gum for Opioid Addiction

The patent was filed for a chewing gum composition with controlled release of cannabinoids and opioid agonists, and antagonists for addiction or dependence treatment.

On June 23, 2017 AXIM Biotechnologies announced that the company had filed for a United States patent for an invention that involves a chewing gum composition with controlled release of cannabinoids and opioid agonists, and/or antagonists for addiction and/or dependence treatment. According to a press release from the company, the gum may also be used for chronic pain depending on its composition.

“Opioid addiction is a serious global problem that affects the health, social, and economic welfare of all societies. Opioid addiction therapy depends on a variety of techniques. One of them is the replacement therapy, where an opioid is replaced with another less potent and less addictive opioid that curbs the craving and reduces withdrawal symptoms, while maintaining the person’s mental state such that the person is still able to function normally,” said George E. Anastassov, MD, DDS, MBA, CEO of AXIM Biotech in a statement.

According to the company, replacement opioids, such as opioid agonists and antagonists and cannabinoids in chewing gum form, may help users avoid adverse effects caused by injecting, smoking, and other drug delivery methods.

Source: AXIM Biotechnologies